where experts go to learn about the FDA
FDA Law Blog where experts go to learn about FDA
Hyman, Phelps & McNamara, P.C.
Menu
Menu
  • Practices
  • Industries
  • FDA Regulatory Categories
  • Professionals
  • About Us
  • Contact
  • LinkedIn
  • Twitter
FDA Law Blog
News & Events
  • LinkedIn
  • Twitter
  • Recent Posts
    • State-Led Food Transparency: Texas and Louisiana Lead the Charge July 10, 2025
    • FDA Softens August 2025 NDSRI Deadline—Progress Reports Now Accepted July 9, 2025
    • HPM’s Larry Houck Speaking at Opioid and Fentanyl Abuse Management Summit July 8, 2025
    • Better Late Than Never: FDA Published FR Notices For De Novo Classifications Dating As Far Back as 2013 July 7, 2025
    • The OTC Fee Fallout: Are Hundreds of Companies Ignoring FDA’s User Fee Requirements? July 3, 2025
  • Trackers
    • 180-Day Exclusivity Tracker
    • FDA Citizen Petition Tracker
    • REMS Tracker (Historical – Not Recently Updated)
    • FDA Legislation Tracker
  • Orange Book Archives

     

    ANDA Paragraph IV Patent Certifications List Archives

  • Scorecards
    • Generic Drug Labeling Carve-Out Scorecard
    • Biosimilars State Legislation Scorecard (Historical – Not Recently Updated) 
  • Blogroll
    • Big Molecule Watch Blog
    • Bloomberg BNA Health Care Blog
    • Drug and Device Law Blog
    • Eye on FDA
    • FDA Matters
    • Harvard Law Bill of Health
    • IN VIVO Blog
    • Internet Drug News.com
    • Lachman Consultants Blog
    • Medical Devices Today
    • Orange Book Blog
    • The Orange Book Insights Blog
    • Pharma IQ
    • Pharmalot
    • SCOTUS Blog
    • The Volokh Conspiracy
    • WLF Legal Pulse
  • Resources
    • Centers for Medicare & Medicaid Services
    • Drug Enforcement Administration
    • Food and Drug Administration
  • Categories
    • Advertising and Promotion (Federal Trade Commission)
    • Advertising and Promotion (OPDP)
    • Animal Drugs and Feeds
    • Biosimilars
    • Cannabis
    • cGMP Compliance
    • Consumer Product Safety Commission
    • Controlled Substances
    • Cosmetics
    • COVID19
    • Current Affairs
    • Dietary Supplements
    • Drug Development
    • Drug Enforcement Administration
    • Enforcement
    • FDA News
    • Foods
    • Foods and Dietary Supplements
    • Fraud and Abuse
    • Government Pricing
    • Hatch-Waxman
    • Health Care
    • Health Privacy
    • Import/Export
    • In Vitro Diagnostic Devices
    • Jobs
    • Medical Devices
    • Miscellaneous
    • Orphan Drugs
    • OTC Drugs and Cosmetics
    • Prescription Drugs and Biologics
    • Product Jurisdiction and Combination Products
    • Reimbursement
    • Tissue Products
    • Tobacco
    • Uncategorized
  • Your search for “Cotizacion de seguros para autos Sonoma CA llama ahora al 888-430-8975 Responsabilidad civil seguro automotor Del seguro contra robos de autos Aseguradora plan seguro Como funciona el seguro de automovil Seguros por meses de coches Seguros coche baratos” returned the following results.

    FDA Law Alert: Issue #2

    …decision lowers the standard for the government to withhold from disclosure confidential commercial or financial information it receives from regulated industry. In their post, Anne Walsh and Ricardo Carvajal describe…

    Holidays and Red Herrings: FDA’s “Nonenforcement Discretion” Successfully Challenged

    …FDA would not be ordered to require egg producers to label commercial eggs as being from “free range” or “cage free” hens, or from “caged hens.” Compassion over Killing v….

    Is the Government All Fired Up About Charging Individuals?

    …false certifications that the products met safety standards. Even though the government touts this case as the “First-Ever Criminal Prosecution for Failure to Report” under the CPSA, the allegations describe…

    AMPed up—again– over Medicaid Rebate False Claims Act allegations

    Earlier this month, the Department of Justice announced another settlement in a Medicaid Rebate False Claims Act (FCA) case. In this case, United States ex rel. Streck v. Bristol-Myers Squibb…

    I Hear You Knockin’… Preparing for and Managing DEA Inspections (Part 2)

    …Investigators may also conduct targeted inspections rather than routine cyclic inspections as part of the local DEA office’s annual workplan if the registrant reported controlled substance thefts/losses or were the…

    DEA Considering Rulemaking on Suspicious Order Reporting

    …DEA may issue a final rule on electronic prescriptions (the agency issued an interim final rule on March 31, 2010) and a proposed rule on transporting controlled substances by ambulance,…

    DEA Proposes Additions to Longstanding Precursor Chemical Special Surveillance List

    …“Laboratory supply,” as defined by the MCA, is “a listed chemical or any chemical, substance, or item on a special surveillance list published by the Attorney General, which contains chemicals,…

    HP&M to Highlight its New FDA Deskbook on Compliance and Enforcement

    …evaluate ramifications of potential enforcement activities, including administrative, civil and criminal actions against it. Register for this webinar here. Participants will receive a copy of Chapters 11 (Devices: Medical Device…

    The Opioid Abuse Deterrence Act and DOJ Initiatives: Just What the Doctor Ordered?

    …force of federal, state, local, and tribal law agencies to identify opioid cases for federal prosecution, facilitate interdiction efforts, and tailor their district’s response to the needs of their communities;…

    FTC Issues Tool Intended to Assess Laws Governing Mobile Health Apps

    …practices that cause, or are likely to cause, substantial injury to consumers that they cannot avoid, and that do more harm than good.” Stating that the FTC Act “may apply”…

    HPM’s Larry Houck Presenting at WCF Opioid and Fentanyl Abuse Management Congress

    …under the federal Controlled Substances Act and DEA regulations pose serious health risks to patients for undertreatment and worse, and to employees for overdose and death. Employee diversion can also…

    Not Content to Just Play the Hits, DOJ’s New Corporate Enforcement Policies Bring A Fresh Spin to Corporate Enforcement

    …that had her audience paying attention, even if they weren’t necessarily singing along. Of course, the traditional corporate enforcement chart-toppers were all there for the DAG. Prevent corporate wrongdoing before…

    CMS Rolls up its Sleeves on Price Negotiations, Sets Agenda for 2026 Negotiated Prices

    …2024. The memorandum is part of CMS’s efforts to engage with the public on the implementation of the Negotiation Program. These efforts also include national stakeholder calls, quarterly strategic meetings,…

    HPM Welcomes 15-Year DOJ Veteran, John W.M. Claud, to the Firm

    …and civil trial litigation and investigations under the Food, Drug, and Cosmetic Act, Federal Trade Commission Act, Consumer Product Safety Act, and Federal data privacy laws. He also held leading…

    FDA Safety Communications: A Potential Provider Pitfall

    …further proceedings in the case. Why this Case Matters This case demonstrates that a court can consider a provider’s actions taken in response to public FDA safety notices when determining…

    Page 37 of 57« First«...1020...363738...4050...»Last »

    Search FDA Law Blog

    Subscribe

    Never miss a post from FDA Law Blog







    Latest Tweets

    Tweets by @fdalawblog

    Awards & Honors

    • Best Lawyers in America® – 2025
    • Ranked in Chambers USA – 2024
  • Recent Posts
    • State-Led Food Transparency: Texas and Louisiana Lead the Charge July 10, 2025
    • FDA Softens August 2025 NDSRI Deadline—Progress Reports Now Accepted July 9, 2025
    • HPM’s Larry Houck Speaking at Opioid and Fentanyl Abuse Management Summit July 8, 2025
    • Better Late Than Never: FDA Published FR Notices For De Novo Classifications Dating As Far Back as 2013 July 7, 2025
    • The OTC Fee Fallout: Are Hundreds of Companies Ignoring FDA’s User Fee Requirements? July 3, 2025
  • Trackers
    • 180-Day Exclusivity Tracker
    • FDA Citizen Petition Tracker
    • REMS Tracker (Historical – Not Recently Updated)
    • FDA Legislation Tracker
  • Orange Book Archives

     

    ANDA Paragraph IV Patent Certifications List Archives

  • Scorecards
    • Generic Drug Labeling Carve-Out Scorecard
    • Biosimilars State Legislation Scorecard (Historical – Not Recently Updated) 
  • Blogroll
    • Big Molecule Watch Blog
    • Bloomberg BNA Health Care Blog
    • Drug and Device Law Blog
    • Eye on FDA
    • FDA Matters
    • Harvard Law Bill of Health
    • IN VIVO Blog
    • Internet Drug News.com
    • Lachman Consultants Blog
    • Medical Devices Today
    • Orange Book Blog
    • The Orange Book Insights Blog
    • Pharma IQ
    • Pharmalot
    • SCOTUS Blog
    • The Volokh Conspiracy
    • WLF Legal Pulse
  • Resources
    • Centers for Medicare & Medicaid Services
    • Drug Enforcement Administration
    • Food and Drug Administration
  • Categories
    • Advertising and Promotion (Federal Trade Commission)
    • Advertising and Promotion (OPDP)
    • Animal Drugs and Feeds
    • Biosimilars
    • Cannabis
    • cGMP Compliance
    • Consumer Product Safety Commission
    • Controlled Substances
    • Cosmetics
    • COVID19
    • Current Affairs
    • Dietary Supplements
    • Drug Development
    • Drug Enforcement Administration
    • Enforcement
    • FDA News
    • Foods
    • Foods and Dietary Supplements
    • Fraud and Abuse
    • Government Pricing
    • Hatch-Waxman
    • Health Care
    • Health Privacy
    • Import/Export
    • In Vitro Diagnostic Devices
    • Jobs
    • Medical Devices
    • Miscellaneous
    • Orphan Drugs
    • OTC Drugs and Cosmetics
    • Prescription Drugs and Biologics
    • Product Jurisdiction and Combination Products
    • Reimbursement
    • Tissue Products
    • Tobacco
    • Uncategorized
  • Copyright 2025 FDA Law Blog HPM
    • Disclaimer
    • Careers